Arabic Arabic English English French French German German
dark

ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, and Helmholtz Munich, announced a cooperation agreement for the clinical development of a radiopharmaceutical therapy candidate to treat malignant brain tumor glioblastoma. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

BridgeBio and Amgen Unite on Combination Therapy for Advanced Solid Tumors

Next Post

FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

Related Posts
Total
0
Share